Plasmablastic lymphoma in a previously undiagnosed human immunodeficiency virus-positive patient: a case report

PBL is extremely aggressive and has a poor response to treatment.5 Plasmablastic lymphoma often affects middle-aged people but may also occur in the pediatric population.6 Classic triad of symptoms including fever, weight loss, and night sweats are usually present in PBL whereas lymphadenopathy is n...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Acta odontologica turcica 2023-09, Vol.40 (3), p.92-95
Hauptverfasser: Yildinmyan, Nelli, Tas, Ayse, Yilmaz, Selmi, Altay, Mehmet All
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 95
container_issue 3
container_start_page 92
container_title Acta odontologica turcica
container_volume 40
creator Yildinmyan, Nelli
Tas, Ayse
Yilmaz, Selmi
Altay, Mehmet All
description PBL is extremely aggressive and has a poor response to treatment.5 Plasmablastic lymphoma often affects middle-aged people but may also occur in the pediatric population.6 Classic triad of symptoms including fever, weight loss, and night sweats are usually present in PBL whereas lymphadenopathy is not among the common symptoms.7 Clinically PBL may resemble periodontal disease, Kaposi sarcoma, or melanoma.6 Even though PBL is difficult to diagnose and distinguish from myeloma or other types of lymphomas, a biopsy is essential in the diagnosis.7 Delayed diagnosis adversely affects the treatment and life expectancy.3 Patients who reject any treatment have a median survival of three months after their diagnosis.8 This case report aims to emphasize the paramount role of biopsy, early clinical suspicion, and correct diagnosis. [...]the patient was advised to take an enzyme-linked immunosorbent assay due to the high possibility of an HIV-infection. A co-infection of Epstein-Barr Virus (EBV) intensifies its aggressive nature.9 The prognosis of PBL is very poor without any treatment and life expectancy is between 1 -24 months.6 The difference in prognosis between HIV-negative and positive patients is uncertain.11 PBL has a male predominance of 75%, which also coincides with our case. Currently, there are no standard guidelines for PBL treatment, instead there are different chemotherapeutic options, most of which include the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone, or the combination of etoposide, prednisone, vincristine, cyclophosphamide and hydroxydaunorubicin, shortly known as CHOP and EPOCH, respectively.13 Autologous or allogeneic hematopoietic stem cell transplantation is another option for PBL; however, its benefit is unclear and is generally used as a consolidation or salvage therapy.15 Several reports claim that autologous hematopoietic stem cell transplantation after the first complete response results in improved remission in PBL and treatment reinforcement in refractory or relapsed PBL patients.16 The literature is supportive of the use of EPOCH, followed by autologous hematopoietic stem cell transplant in eligible patients, due to its better outcomes than CHOP.17 A similar treatment plan was followed for the present case, as well.
doi_str_mv 10.17214/qaziaot.1177114
format Article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_2864644510</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2864644510</sourcerecordid><originalsourceid>FETCH-proquest_journals_28646445103</originalsourceid><addsrcrecordid>eNqNjDFPwzAQhS0kpFbQndESc4ovdZPCikCMDAzdqiNx26tin-uzI4VfTwZ-AMt70vc9PaUewKyhrcE-XfGHkPMaoG0B7I1azrStmmezX6iVyMUYA7vtBpp6qfhzQPH4PWemTg-Tj2f2qClo1DG5kbjIMOkSesJTYHG9PhePQZP3JXDvjtSRC92kR0pFqshCmUanI-aZ55f5p0NxOrnIKd-r2yMO4lZ_face39--Xj-qmPhanOTDhUsKszrUu8Y21m7BbP63-gXBG1KC</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2864644510</pqid></control><display><type>article</type><title>Plasmablastic lymphoma in a previously undiagnosed human immunodeficiency virus-positive patient: a case report</title><source>DOAJ Directory of Open Access Journals</source><creator>Yildinmyan, Nelli ; Tas, Ayse ; Yilmaz, Selmi ; Altay, Mehmet All</creator><creatorcontrib>Yildinmyan, Nelli ; Tas, Ayse ; Yilmaz, Selmi ; Altay, Mehmet All</creatorcontrib><description>PBL is extremely aggressive and has a poor response to treatment.5 Plasmablastic lymphoma often affects middle-aged people but may also occur in the pediatric population.6 Classic triad of symptoms including fever, weight loss, and night sweats are usually present in PBL whereas lymphadenopathy is not among the common symptoms.7 Clinically PBL may resemble periodontal disease, Kaposi sarcoma, or melanoma.6 Even though PBL is difficult to diagnose and distinguish from myeloma or other types of lymphomas, a biopsy is essential in the diagnosis.7 Delayed diagnosis adversely affects the treatment and life expectancy.3 Patients who reject any treatment have a median survival of three months after their diagnosis.8 This case report aims to emphasize the paramount role of biopsy, early clinical suspicion, and correct diagnosis. [...]the patient was advised to take an enzyme-linked immunosorbent assay due to the high possibility of an HIV-infection. A co-infection of Epstein-Barr Virus (EBV) intensifies its aggressive nature.9 The prognosis of PBL is very poor without any treatment and life expectancy is between 1 -24 months.6 The difference in prognosis between HIV-negative and positive patients is uncertain.11 PBL has a male predominance of 75%, which also coincides with our case. Currently, there are no standard guidelines for PBL treatment, instead there are different chemotherapeutic options, most of which include the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone, or the combination of etoposide, prednisone, vincristine, cyclophosphamide and hydroxydaunorubicin, shortly known as CHOP and EPOCH, respectively.13 Autologous or allogeneic hematopoietic stem cell transplantation is another option for PBL; however, its benefit is unclear and is generally used as a consolidation or salvage therapy.15 Several reports claim that autologous hematopoietic stem cell transplantation after the first complete response results in improved remission in PBL and treatment reinforcement in refractory or relapsed PBL patients.16 The literature is supportive of the use of EPOCH, followed by autologous hematopoietic stem cell transplant in eligible patients, due to its better outcomes than CHOP.17 A similar treatment plan was followed for the present case, as well.</description><identifier>EISSN: 2147-690X</identifier><identifier>DOI: 10.17214/qaziaot.1177114</identifier><language>eng</language><publisher>Ankara: Gazi University Faculty of Dentistry (Acta Odontologica Turcica)</publisher><subject>Autografts ; Biopsy ; Bone marrow ; Case reports ; Chemotherapy ; Cyclophosphamide ; Dental implants ; Diagnosis ; Doxorubicin ; Enzyme-linked immunosorbent assay ; Epstein-Barr virus ; Etoposide ; Gum disease ; Hematopoietic stem cells ; HIV ; Human immunodeficiency virus ; Immune system ; Infections ; Kaposis sarcoma ; Life expectancy ; Life span ; Lymphadenopathy ; Lymphoma ; Medical prognosis ; Melanoma ; Myeloma ; Patients ; Pediatrics ; Periodontal diseases ; Prednisone ; Prognosis ; Remission ; Remission (Medicine) ; Sarcoma ; Stem cell transplantation ; Vincristine</subject><ispartof>Acta odontologica turcica, 2023-09, Vol.40 (3), p.92-95</ispartof><rights>2023. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,27924,27925</link.rule.ids></links><search><creatorcontrib>Yildinmyan, Nelli</creatorcontrib><creatorcontrib>Tas, Ayse</creatorcontrib><creatorcontrib>Yilmaz, Selmi</creatorcontrib><creatorcontrib>Altay, Mehmet All</creatorcontrib><title>Plasmablastic lymphoma in a previously undiagnosed human immunodeficiency virus-positive patient: a case report</title><title>Acta odontologica turcica</title><description>PBL is extremely aggressive and has a poor response to treatment.5 Plasmablastic lymphoma often affects middle-aged people but may also occur in the pediatric population.6 Classic triad of symptoms including fever, weight loss, and night sweats are usually present in PBL whereas lymphadenopathy is not among the common symptoms.7 Clinically PBL may resemble periodontal disease, Kaposi sarcoma, or melanoma.6 Even though PBL is difficult to diagnose and distinguish from myeloma or other types of lymphomas, a biopsy is essential in the diagnosis.7 Delayed diagnosis adversely affects the treatment and life expectancy.3 Patients who reject any treatment have a median survival of three months after their diagnosis.8 This case report aims to emphasize the paramount role of biopsy, early clinical suspicion, and correct diagnosis. [...]the patient was advised to take an enzyme-linked immunosorbent assay due to the high possibility of an HIV-infection. A co-infection of Epstein-Barr Virus (EBV) intensifies its aggressive nature.9 The prognosis of PBL is very poor without any treatment and life expectancy is between 1 -24 months.6 The difference in prognosis between HIV-negative and positive patients is uncertain.11 PBL has a male predominance of 75%, which also coincides with our case. Currently, there are no standard guidelines for PBL treatment, instead there are different chemotherapeutic options, most of which include the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone, or the combination of etoposide, prednisone, vincristine, cyclophosphamide and hydroxydaunorubicin, shortly known as CHOP and EPOCH, respectively.13 Autologous or allogeneic hematopoietic stem cell transplantation is another option for PBL; however, its benefit is unclear and is generally used as a consolidation or salvage therapy.15 Several reports claim that autologous hematopoietic stem cell transplantation after the first complete response results in improved remission in PBL and treatment reinforcement in refractory or relapsed PBL patients.16 The literature is supportive of the use of EPOCH, followed by autologous hematopoietic stem cell transplant in eligible patients, due to its better outcomes than CHOP.17 A similar treatment plan was followed for the present case, as well.</description><subject>Autografts</subject><subject>Biopsy</subject><subject>Bone marrow</subject><subject>Case reports</subject><subject>Chemotherapy</subject><subject>Cyclophosphamide</subject><subject>Dental implants</subject><subject>Diagnosis</subject><subject>Doxorubicin</subject><subject>Enzyme-linked immunosorbent assay</subject><subject>Epstein-Barr virus</subject><subject>Etoposide</subject><subject>Gum disease</subject><subject>Hematopoietic stem cells</subject><subject>HIV</subject><subject>Human immunodeficiency virus</subject><subject>Immune system</subject><subject>Infections</subject><subject>Kaposis sarcoma</subject><subject>Life expectancy</subject><subject>Life span</subject><subject>Lymphadenopathy</subject><subject>Lymphoma</subject><subject>Medical prognosis</subject><subject>Melanoma</subject><subject>Myeloma</subject><subject>Patients</subject><subject>Pediatrics</subject><subject>Periodontal diseases</subject><subject>Prednisone</subject><subject>Prognosis</subject><subject>Remission</subject><subject>Remission (Medicine)</subject><subject>Sarcoma</subject><subject>Stem cell transplantation</subject><subject>Vincristine</subject><issn>2147-690X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqNjDFPwzAQhS0kpFbQndESc4ovdZPCikCMDAzdqiNx26tin-uzI4VfTwZ-AMt70vc9PaUewKyhrcE-XfGHkPMaoG0B7I1azrStmmezX6iVyMUYA7vtBpp6qfhzQPH4PWemTg-Tj2f2qClo1DG5kbjIMOkSesJTYHG9PhePQZP3JXDvjtSRC92kR0pFqshCmUanI-aZ55f5p0NxOrnIKd-r2yMO4lZ_face39--Xj-qmPhanOTDhUsKszrUu8Y21m7BbP63-gXBG1KC</recordid><startdate>20230901</startdate><enddate>20230901</enddate><creator>Yildinmyan, Nelli</creator><creator>Tas, Ayse</creator><creator>Yilmaz, Selmi</creator><creator>Altay, Mehmet All</creator><general>Gazi University Faculty of Dentistry (Acta Odontologica Turcica)</general><scope>3V.</scope><scope>7QP</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>EDSIH</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope></search><sort><creationdate>20230901</creationdate><title>Plasmablastic lymphoma in a previously undiagnosed human immunodeficiency virus-positive patient: a case report</title><author>Yildinmyan, Nelli ; Tas, Ayse ; Yilmaz, Selmi ; Altay, Mehmet All</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_28646445103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Autografts</topic><topic>Biopsy</topic><topic>Bone marrow</topic><topic>Case reports</topic><topic>Chemotherapy</topic><topic>Cyclophosphamide</topic><topic>Dental implants</topic><topic>Diagnosis</topic><topic>Doxorubicin</topic><topic>Enzyme-linked immunosorbent assay</topic><topic>Epstein-Barr virus</topic><topic>Etoposide</topic><topic>Gum disease</topic><topic>Hematopoietic stem cells</topic><topic>HIV</topic><topic>Human immunodeficiency virus</topic><topic>Immune system</topic><topic>Infections</topic><topic>Kaposis sarcoma</topic><topic>Life expectancy</topic><topic>Life span</topic><topic>Lymphadenopathy</topic><topic>Lymphoma</topic><topic>Medical prognosis</topic><topic>Melanoma</topic><topic>Myeloma</topic><topic>Patients</topic><topic>Pediatrics</topic><topic>Periodontal diseases</topic><topic>Prednisone</topic><topic>Prognosis</topic><topic>Remission</topic><topic>Remission (Medicine)</topic><topic>Sarcoma</topic><topic>Stem cell transplantation</topic><topic>Vincristine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yildinmyan, Nelli</creatorcontrib><creatorcontrib>Tas, Ayse</creatorcontrib><creatorcontrib>Yilmaz, Selmi</creatorcontrib><creatorcontrib>Altay, Mehmet All</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Turkey Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><jtitle>Acta odontologica turcica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yildinmyan, Nelli</au><au>Tas, Ayse</au><au>Yilmaz, Selmi</au><au>Altay, Mehmet All</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Plasmablastic lymphoma in a previously undiagnosed human immunodeficiency virus-positive patient: a case report</atitle><jtitle>Acta odontologica turcica</jtitle><date>2023-09-01</date><risdate>2023</risdate><volume>40</volume><issue>3</issue><spage>92</spage><epage>95</epage><pages>92-95</pages><eissn>2147-690X</eissn><abstract>PBL is extremely aggressive and has a poor response to treatment.5 Plasmablastic lymphoma often affects middle-aged people but may also occur in the pediatric population.6 Classic triad of symptoms including fever, weight loss, and night sweats are usually present in PBL whereas lymphadenopathy is not among the common symptoms.7 Clinically PBL may resemble periodontal disease, Kaposi sarcoma, or melanoma.6 Even though PBL is difficult to diagnose and distinguish from myeloma or other types of lymphomas, a biopsy is essential in the diagnosis.7 Delayed diagnosis adversely affects the treatment and life expectancy.3 Patients who reject any treatment have a median survival of three months after their diagnosis.8 This case report aims to emphasize the paramount role of biopsy, early clinical suspicion, and correct diagnosis. [...]the patient was advised to take an enzyme-linked immunosorbent assay due to the high possibility of an HIV-infection. A co-infection of Epstein-Barr Virus (EBV) intensifies its aggressive nature.9 The prognosis of PBL is very poor without any treatment and life expectancy is between 1 -24 months.6 The difference in prognosis between HIV-negative and positive patients is uncertain.11 PBL has a male predominance of 75%, which also coincides with our case. Currently, there are no standard guidelines for PBL treatment, instead there are different chemotherapeutic options, most of which include the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone, or the combination of etoposide, prednisone, vincristine, cyclophosphamide and hydroxydaunorubicin, shortly known as CHOP and EPOCH, respectively.13 Autologous or allogeneic hematopoietic stem cell transplantation is another option for PBL; however, its benefit is unclear and is generally used as a consolidation or salvage therapy.15 Several reports claim that autologous hematopoietic stem cell transplantation after the first complete response results in improved remission in PBL and treatment reinforcement in refractory or relapsed PBL patients.16 The literature is supportive of the use of EPOCH, followed by autologous hematopoietic stem cell transplant in eligible patients, due to its better outcomes than CHOP.17 A similar treatment plan was followed for the present case, as well.</abstract><cop>Ankara</cop><pub>Gazi University Faculty of Dentistry (Acta Odontologica Turcica)</pub><doi>10.17214/qaziaot.1177114</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier EISSN: 2147-690X
ispartof Acta odontologica turcica, 2023-09, Vol.40 (3), p.92-95
issn 2147-690X
language eng
recordid cdi_proquest_journals_2864644510
source DOAJ Directory of Open Access Journals
subjects Autografts
Biopsy
Bone marrow
Case reports
Chemotherapy
Cyclophosphamide
Dental implants
Diagnosis
Doxorubicin
Enzyme-linked immunosorbent assay
Epstein-Barr virus
Etoposide
Gum disease
Hematopoietic stem cells
HIV
Human immunodeficiency virus
Immune system
Infections
Kaposis sarcoma
Life expectancy
Life span
Lymphadenopathy
Lymphoma
Medical prognosis
Melanoma
Myeloma
Patients
Pediatrics
Periodontal diseases
Prednisone
Prognosis
Remission
Remission (Medicine)
Sarcoma
Stem cell transplantation
Vincristine
title Plasmablastic lymphoma in a previously undiagnosed human immunodeficiency virus-positive patient: a case report
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T08%3A48%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Plasmablastic%20lymphoma%20in%20a%20previously%20undiagnosed%20human%20immunodeficiency%20virus-positive%20patient:%20a%20case%20report&rft.jtitle=Acta%20odontologica%20turcica&rft.au=Yildinmyan,%20Nelli&rft.date=2023-09-01&rft.volume=40&rft.issue=3&rft.spage=92&rft.epage=95&rft.pages=92-95&rft.eissn=2147-690X&rft_id=info:doi/10.17214/qaziaot.1177114&rft_dat=%3Cproquest%3E2864644510%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2864644510&rft_id=info:pmid/&rfr_iscdi=true